Cochlear Ltd (ASX: COH) is one of the world’s leading medical businesses. Cochlear designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Graeme Clark invented the first device in 1982, allowing first-user Graham Carrick to hear for the first time for 17 years. Some of the most recent modifications allow users to play sound from their phone directly into their implant.
The Cochlear Ltd (ASX:COH) share price fell 14% on Friday after the hearing device stock announced its HY25 result.
John Addis is the founder of Intelligent Investor and author of How Not to Lose $1 Million: Win at investing by losing less. He joins Owen Rask on this Rask podcast.
Drew Meredith, CFP and Owen Rask dive into Emerging Markets 102, picking small and mid-cap ASX fund managers, whether or not to use an SMSF and more.
The Cochlear Ltd (ASX:COH) share price dropped 7% in response to the company’s FY24 result and FY25 outlook.
The local market was buoyed by another strong day of reporting by Australia’s largest companies, with both the All Ordinaries (INDEXASX: XAO) and S&P/ASX 200 (INDEXASX: XJO) gaining 0.3 per cent on Thursday.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.31% to 7,639.20.
The Cochlear Limited (ASX:COH) share price is up 4% after the ASX healthcare share revealed a strong FY24 earnings update.
The S&P/ASX200 (INDEXASX: XJO) down 0.6 per cent with the energy sector, up 0.4 per cent, the only highlight.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.057% to 7,519.20.
